A European network to improve cancer treatment
The OASIS Consortium
Launched in January 2025, OASIS is an international biomedical research program coordinated by Gustave Roussy. It brings together a consortium of 12 partners across Europe, united by a common goal: improving cancer treatment.
Presentation
Launched in January 2025, OASIS is an international biomedical research program coordinated by Gustave Roussy. It brings together a consortium of 12 partners across Europe, united by a common goal: improving cancer treatment.
Among them are industrial partners such as Olink Proteomics AB, as well as two biomedical start-ups spun out of Gustave Roussy — Elikya Therapeutics and Orakl Oncology. The project also includes academic partners such as CentraleSupélec, UNICANCER, Inserm, the Jules Bordet Institute, the Atomic Energy and Alternative Energies Commission (CEA), the University of Athens, and the University Hospital of Heraklion in Crete, as well as the Cancer Patients Europe patient association.
Gustave Roussy - Coordinator of the program
Gustave Roussy is Europe’s first cancer center, bringing together 4,000 professionals on a single site dedicated to care, research, and education in oncology. The institute treats both adults and children with common or rare cancers, at all stages of the disease, in a facility where medical care, research, and teaching are closely integrated. Its expertise and cutting-edge clinical practices make it a reference center in France and internationally.
Gustave Roussy also upholds a long-standing tradition of patient-centered care, driven by the belief that beyond medical and scientific excellence, quality care also means supporting the person as a whole.
It is a non-profit private healthcare institution of collective interest (ESPIC), authorized to receive donations and bequests. Gustave Roussy is part of the network of 20 French Comprehensive Cancer Centers (CLCC), a special status established by the French Public Health Code.
4,000 full-time employees
including 660 physicians, 1,230 healthcare professionals, and 1,400 research staff
50,000 patients treated in 2024
including 12,000 new patients
35 research teams · 145 publications
in international journals with an impact factor above 30 (excluding congress abstracts)
2,888 students trained
and 4,618 enrolled on the e-learning platform
An international Consortium
Interactive Consortium Map
Explore the geographic distribution of European partners. Hover over the markers to discover each partner's details and click to access complete information.
🇫🇷 France
7 partners
Coordinator
Gustave Roussy
📍 Villejuif
Coordinating institute of the OASIS project.
Clinical
UNICANCER
📍 Paris
France’s network of Comprehensive Cancer Centers; coordinates the OASIS clinical trial across participating countries.
Learn more
The only hospital network in France entirely dedicated to the fight against cancer. As the leading academic sponsor of oncology clinical trials in Europe, UNICANCER is recognized for its expertise in both clinical and translational research.
Within the OASIS project, UNICANCER coordinates the clinical trials conducted across participating countries, including France, Belgium, and Greece.
Academic
INSERM
📍 Paris
French National Institute of Health and Medical Research.
Learn more
Three INSERM research units will be involved in the OASIS project:
- Unit U1279, led by Guillaume Montagnac, focusing on tumor cell dynamics
- Unit U981, led by Fabrice André, specializing in decoding the molecular landscapes of cancers
- The Oncostat team led by Stefan Michiels, within UMR 1018, providing expertise in clinical trial methodology and statistical analysis
Academic
CentraleSupélec
📍 Saclay
French institution of higher education and research in engineering sciences; leads AI interpretability methods.
Learn more
The Mathematics and Computer Science Laboratory (MICS) at CentraleSupélec, specialized in the analysis of complex systems and data, has been conducting in-depth oncology research for several years.
Within the OASIS program, CentraleSupélec plays a key role in developing algorithms for AI-based analysis of tumor biopsies, as well as in creating the predictive score for response and toxicity to ADCs based on clinical, molecular, and imaging data.
Academic
CEA
📍 Saclay
French Alternative Energies and Atomic Energy Commission.
Learn more
CEA is ranked among the 100 most innovative companies worldwide according to the Clarivate ranking.
Within the OASIS project, the CEA’s medical imaging department—including radiological, nuclear, and ultrasound imaging—will be involved in developing new radiotracers to perform PET scans that evaluate the expression of certain ADC targets such as TROP2 and NECTIN-4.
Industrial
Elikya Therapeutics
📍 Strasbourg
Biotech spun out of Paris-Saclay University and the Gustave Roussy Institute.
Learn more
Based in Strasbourg, this biotech company develops new generations of antibody-drug conjugates (ADCs) based on innovative toxic payload technologies, targeting both the tumor and its microenvironment.
Within the OASIS project, Elikya will be responsible for developing a new ADC. This ADC will be designed using data generated by the project and aims to overcome resistance to ADCs currently used in clinical practice.
Industrial
Orakl Oncology
📍 Paris
French biotech spun out of Gustave Roussy, dedicated to accelerating drug discovery in oncology.
Learn more
Orakl holds a unique and exclusive license on the expertise developed at the Institut Gustave Roussy (IGR), which has generated over 150 patient-derived organoids (PDOs) from colorectal and pancreatic cancer biopsies.
Within the OASIS project, ORAKL contributes its expertise in developing organoids derived from tumor biopsies and conducting complex analyses to identify the mechanisms involved in resistance to ADCs.
🇧🇪 Belgium
1 partner
Academic
Jules Bordet Institute (IJB)
📍 Bruxelles
Integrated, multidisciplinary cancer center in Belgium, fully dedicated to oncology.
Learn more
The IJB’s Nuclear Medicine Department is a pioneer in molecular imaging and theranostic approaches. Several radiotracers have been developed and implemented there for the first time.
Within the framework of the OASIS project, the IJB will develop a PET scan using Zr89-trastuzumab to predict response to trastuzumab deruxtecan (an ADC targeting HER2) in patients participating in the study in Belgium.
🇬🇷 Greece
2 partners
Academic
National and Kapodistrian University of Athens (NKUA)
📍 Athens
Participates in OASIS through its circulating tumor cell laboratory.
Learn more
The University of Athens is considered one of the leading universities of Greece, a leading European regional university and is present in the top universities annual lists.
NKUA will participate in the OASIS project through the ACTC laboratory (Analysis of Circulating Tumor Cells), which specializes in liquid biopsy analysis, circulating tumor cells (CTCs), and circulating free DNA.
Clinical
University of Crete (UoC)
📍 Heraklion
Multidisciplinary research-based institution located in Crete, Greece.
Learn more
The University of Crete (UoC) is a multidisciplinary research-focused institution located on the island of Crete in Greece, recognized as one of the most prestigious academic institutions in the country.
Within the OASIS project, UoC is represented by the Department of Medical Oncology which provides comprehensive cancer care services. UoC will also operate as a participating center for the OASIS clinical trials.
🇸🇪 Sweden
1 partner
Industrial
Olink
📍 Uppsala
Proteomics company within Thermo Fisher Scientific.
Learn more
Its mission is to accelerate proteomics development in collaboration with the scientific community to better understand real-time biology and provide actionable insights into human health and disease.
Within the OASIS project, Olink technology will be used to better understand resistance and toxicity mechanisms related to ADCs, as well as to develop biomarkers to identify patients at risk of severe toxicities.
🇪🇺 Europe
1 partner
Patients
Cancer Patients Europe (CPE)
📍 Multi-country
Pan-European association bringing together cancer patients, their caregivers, and advocates.
Learn more
Its mission is to reduce the burden of cancer on patients and survivors, their caregivers, healthcare systems, and society as a whole across Europe. CPE currently has 40 members spread across 20 countries.
Within the OASIS program, CPE plays a key role in enhancing patient understanding and accessibility of the project, as well as in shaping future implementation strategies.